Last qtr, Arixtra sales in the US fell from US$12m to US$11m, so they hardly 'fell sharply'.
The rest of the world sales rose from US$7m to US$13m, which is a huge increase for just one qtr. The qtr before was US$4m, so up 225% in half a year.
Once the Lancet reports on Arixtra's advantages over other heparins, the sales really will fly.
just my (bias) opinion.
- Forums
- ASX - By Stock
- re:gsk quarterly rsults
Last qtr, Arixtra sales in the US fell from US$12m to US$11m, so...
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable